• Explore /
  • Poster
  • / An open-label, pharmacokinetic study to determine the bioavailability, safety and tolerability of single dose oral docetaxel in metastatic prostate cancer (mPC) patients treated with IV docetaxel.

An open-label, pharmacokinetic study to determine the bioavailability, safety and tolerability of single dose oral docetaxel in metastatic prostate cancer (mPC) patients treated with IV docetaxel.

Abstract Poster

Authors

null

Christopher G. C. A. Jackson

Dunedin Hospital, Dunedin, New Zealand

Christopher G. C. A. Jackson , Yen-chuan Ou , Meng En , Tsu-Yi Chao , Noelyn Anne Hung , David Wang , David Cutler , Douglas Kramer , Jay Zhi , Wing Kai Chan , Min-Fun Rudolf Kwan , Tak Hung

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

12616000983404

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 5050)

DOI

10.1200/JCO.2021.39.15_suppl.5050

Abstract #

5050

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Funda Meric-Bernstam

First Author: Marit Vermunt

First Author: Mark N. Stein

Poster

2015 Genitourinary Cancers Symposium

Phase 1/2a, open-label, dose-escalation and safety study of APC-100 in men with advanced prostate cancer.

Phase 1/2a, open-label, dose-escalation and safety study of APC-100 in men with advanced prostate cancer.

First Author: Christos Kyriakopoulos